Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Posaconazole pharmacokinetics and safety in children younger than 2 years with invasive fungal infection
2019-003842-34Phase 2Active
- Sponsor
- Merck & Co.
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of posaconazole in invasive mycoses (2 arms), sponsored by Merck & Co. Primary endpoint: Average concentration of single-dose intravenous posaconazole. Started Sep 2020; status: active.
02
Drugs
posaconazole
03
Conditions
invasive mycoses
Beyond the preview
Go deeper on 2019-003842-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003842-34.